Solid Biosciences
SLDB
92 hedge funds and large institutions have $250M invested in Solid Biosciences in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 13 closing their positions.
1,582% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $268K
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
17% more capital invested
Capital invested by funds: $213M → $250M (+$36.6M)
15% more funds holding
Funds holding: 80 → 92 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.09% less ownership
Funds ownership: 97.96% → 92.86% (-5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.55M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.68M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.92M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.29M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$14.2M |
| 2 |
DM
Deerfield Management
New York
|
-$9.89M |
| 3 |
Millennium Management
New York
|
-$4.95M |
| 4 |
Janus Henderson Group
London,
|
-$4.33M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.23M |
SLDB Hedge Fund Activity: Q3 2024 in Review
92 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q3 2024, worth a combined $250M — up 17% from $213M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SLDB positions and 13 closed out — a net gain of 13 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $6.55M. The largest seller was Artal Group, exiting entirely with an estimated $14.2M sold.
- 92 institutional investors held Solid Biosciences (SLDB) as of Q3 2024, up from 80 in Q2 2024.
- Funds reported $250M of Solid Biosciences stock for Q3 2024, up 17% quarter-over-quarter.
- 26 funds opened new Solid Biosciences positions in Q3 2024 and 13 closed out, a net change of +13 holders.
- The largest Solid Biosciences buyer in Q3 2024 was Citadel Advisors, an estimated $6.55M added.
- The largest Solid Biosciences seller in Q3 2024 was Artal Group, an estimated $14.2M sold.
Based on aggregated 13F filings for Q3 2024.